Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rhythm Biosciences Ltd. ( (AU:RHY) ) just unveiled an update.
Rhythm Biosciences has issued 1,000,000 new ordinary shares on 16 January 2026 and has lodged a cleansing notice confirming that the shares were issued without a prospectus under the Corporations Act disclosure exemptions. The company states it remains compliant with its financial reporting and continuous disclosure obligations and that there is no excluded information requiring disclosure, providing investors with assurance around regulatory compliance as it continues to advance and commercialise its cancer diagnostics offerings, including its ColoSTAT colorectal cancer blood test.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on developing simple, affordable blood tests for the accurate and early detection of cancers, with a particular emphasis on colorectal cancer. Founded in 2017 and headquartered in Melbourne, the company’s lead product is ColoSTAT, a blood-based test kit that measures specific protein biomarkers to assess colorectal cancer risk, and it also references the geneType genetic risk assessment platform, positioning Rhythm within the broader preventative healthcare and precision medicine markets.
Average Trading Volume: 466,433
Technical Sentiment Signal: Buy
Current Market Cap: A$45.5M
See more data about RHY stock on TipRanks’ Stock Analysis page.